Henry J Pownall

List of Publications by Year
in descending order

224	12,485	31902	29081
papers	citations	53 h-index	104 g-index

230	230	230	11768
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association Between Change in Accelerometer-Measured and Self-Reported Physical Activity and Cardiovascular Disease in the Look AHEAD Trial. Diabetes Care, 2022, 45, 742-749.	4.3	10
2	Free Cholesterol Bioavailability and Atherosclerosis. Current Atherosclerosis Reports, 2022, 24, 323-336.	2.0	10
3	Poloxamer 407 Induces Hypertriglyceridemia but Decreases Atherosclerosis in Ldlrâˆ’/âˆ’ Mice. Cells, 2022, 11, 1795.	1.8	4
4	High-Density Lipoprotein Processing and Premature Cardiovascular Disease. Methodist DeBakey Cardiovascular Journal, 2021, 11, 181.	0.5	4
5	Native and Reconstituted Plasma Lipoproteins in Nanomedicine: Physicochemical Determinants of Nanoparticle Structure, Stability, and Metabolism. Methodist DeBakey Cardiovascular Journal, 2021, 12, 146.	0.5	13
6	Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study. Diabetes Care, 2021, 44, 67-74.	4.3	10
7	High-density lipoproteins, reverse cholesterol transport and atherogenesis. Nature Reviews Cardiology, 2021, 18, 712-723.	6.1	91
8	Physico-chemical and physiological determinants of lipo-nanoparticle stability. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 33, 102361.	1.7	4
9	High Free Cholesterol Bioavailability Drives the Tissue Pathologies in Scarb1 âˆ’/âˆ’ Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, e453-e467.	1.1	9
10	Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability. Methodist DeBakey Cardiovascular Journal, 2021, 15, 47.	0.5	18
11	Cholesterol: Canâ€™t Live With It, Canâ€™t Live Without It. Methodist DeBakey Cardiovascular Journal, 2021, 15, 9.	0.5	8
12	Lipids and Cardiovascular Disease: Putting It All Together. Methodist DeBakey Cardiovascular Journal, 2021, 15, 5.	0.5	6
13	Replacing Saturated Fat With Unsaturated Fat in Western Diet Reduces Foamy Monocytes and Atherosclerosis in Male Ldlr ^{â€“/â€“} Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 72-85.	1.1	20
14	History of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD Trial. Obesity, 2020, 28, 247-258.	1.5	8
15	Highly conserved amino acid residues in apolipoprotein A1 discordantly induce high density lipoprotein assembly in vitro and in vivo. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158794.	1.2	3
16	Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. Obesity, 2020, 28, 1678-1686.	1.5	47
17	Commentary on SSO and other putative inhibitors of FA transport across membranes by CD36 disrupt intracellular metabolism, but do not affect fatty acid translocation. Journal of Lipid Research, 2020, 61, 595-597.	2.0	7
18	The Alcoholâ€“High-Density Lipoprotein Athero-Protective Axis. Biomolecules, 2020, 10, 987.	1.8	7

#	Article	IF	Citations
19	Dietary Alcohol and Fat Differentially Affect Plasma Cholesteryl Ester Transfer Activity and Triglycerides in Normoâ€•and Hypertriglyceridemic Subjects. Lipids, 2020, 55, 299-307.	0.7	4
20	Weight Change 2 Years After Termination of the Intensive Lifestyle Intervention in the Look AHEAD Study. Obesity, 2020, 28, 893-901.	1.5	24
21	Vulnerable Atherosclerotic Plaque Imaging by Smallâ€Molecule Highâ€Affinity Positron Emission Tomography Radiopharmaceutical. Advanced Therapeutics, 2019, 2, 1900005.	1.6	2
22	Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins. Journal of Clinical Lipidology, 2018, 12, 849-856.	0.6	34
23	Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1552-1559.	1.7	39
24	Rethinking apolipoprotein A-II in lipid metabolism. American Journal of Clinical Nutrition, 2018, 108, 4-5.	2.2	2
25	Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1997-2006.	1.1	63
26	Effects of visceral adipose tissue reduction on CVD risk factors independent of weight loss: The Look AHEAD study. Endocrine Research, 2017, 42, 86-95.	0.6	3
27	Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment. Neurology, 2017, 88, 2026-2035.	1.5	59
28	AIBP Limits Angiogenesis Through Î³-Secretase-Mediated Upregulation of Notch Signaling. Circulation Research, 2017, 120, 1727-1739.	2.0	49
29	Scavenger receptor B1 (SR-B1) profoundly excludes high density lipoprotein (HDL) apolipoprotein AII as it nibbles HDL-cholesteryl ester. Journal of Biological Chemistry, 2017, 292, 8864-8873.	1.6	35
30	Structural Stability of Streptococcal Serum Opacity Factor. Protein Journal, 2017, 36, 196-201.	0.7	0
31	Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. Scientific Reports, 2017, 7, 44624.	1.6	76
32	ABCA1-Derived Nascent High-Density Lipoproteinâ€“Apolipoprotein AI and Lipids Metabolically SegregateHighlights. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 2260-2270.	1.1	34
33	The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial. Journal of Bone and Mineral Research, 2017, 32, 2278-2287.	3.1	57
34	Acylation of lysine residues in human plasma high density lipoprotein increases stability and plasma clearance in vivo. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1787-1795.	1.2	0
35	Neo High-Density Lipoprotein Produced by the Streptococcal Serum Opacity Factor Activity against Human High-Density Lipoproteins Is Hepatically Removed via Dual Mechanisms. Biochemistry, 2016, 55, 5845-5853.	1.2	5
36	Changes in regional body composition over 8 years in a randomized lifestyle trial: The look AHEAD study. Obesity, 2016, 24, 1899-1905.	1.5	8

#	Article	IF	Citations
37	Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 913-921.	5.5	473
38	Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. Diabetes Care, 2016, 39, 1345-1355.	4.3	91
39	New Insights into the High-Density Lipoprotein Dilemma. Trends in Endocrinology and Metabolism, 2016, 27, 44-53.	3.1	15
40	Direct Measurement of the Structure of Reconstituted High-Density Lipoproteins by Cryo-EM. Biophysical Journal, 2016, 110, 810-816.	0.2	15
41	Streptococcal serum opacity factor promotes cholesterol ester metabolism and bile acid secretion in vitro and in vivo. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 196-204.	1.2	5
42	Alcohol: A Nutrient with Multiple Salutary Effects. Nutrients, 2015, 7, 1992-2000.	1.7	8
43	Estrogen: An Emerging Regulator of Insulin Action and Mitochondrial Function. Journal of Diabetes Research, 2015, 2015, 1-9.	1.0	134
44	Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: The look AHEAD study. Obesity, 2015, 23, 565-572.	1.5	55
45	Apolipoprotein AI Deficiency Inhibits Serum Opacity Factor Activity against Plasma High Density Lipoprotein via a Stabilization Mechanism. Biochemistry, 2015, 54, 2295-2302.	1.2	5
46	Prevention and Treatment of Atherosclerotic Vascular Disease: Hypolipidemic Agents. , 2015, , 589-611.		0
47	Commentary on Fatty Acid Wars. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, e8-9.	1.1	18
48	Impact of Intensive Lifestyle Intervention on Depression and Health-Related Quality of Life in Type 2 Diabetes: The Look AHEAD Trial. Diabetes Care, 2014, 37, 1544-1553.	4.3	178
49	Impact of an Intensive Lifestyle Intervention on Use and Cost of Medical Services Among Overweight and Obese Adults With Type 2 Diabetes: The Action for Health in Diabetes. Diabetes Care, 2014, 37, 2548-2556.	4.3	144
50	Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. Journal of Clinical Lipidology, 2013, 7, 661-670.	0.6	19
51	Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: Further evidence for a unique form of Metabolic Syndrome in HIV patients. Metabolism: Clinical and Experimental, 2013, 62, 1014-1020.	1.5	29
52	Free Cholesterol Determines Reassembled High-Density Lipoprotein Phospholipid Phase Structure and Stability. Biochemistry, 2013, 52, 4324-4330.	1.2	7
53	Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 145-154.	13.9	2,294
54	Relationship of ethnicity and CD4 Count with glucose metabolism among HIV patients on Highly-Active Antiretroviral Therapy (HAART). BMC Endocrine Disorders, 2013, 13, 13.	0.9	8

#	Article	IF	Citations
55	Setting the course for apoAII: a port in sight?. Clinical Lipidology, 2013, 8, 551-560.	0.4	10
56	Do Genetic Modifiers of High-Density Lipoprotein Cholesterol and Triglyceride Levels Also Modify Their Response to a Lifestyle Intervention in the Setting of Obesity and Type-2 Diabetes Mellitus?. Circulation: Cardiovascular Genetics, 2013, 6, 391-399.	5.1	30
57	Impaired Lipoprotein Processing in HIV Patients on Antiretroviral Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1714-1721.	1.1	23
58	Intensive Lifestyle Modification Reduces Lp-PLA2 in Dyslipidemic HIV/HAART Patients. Medicine and Science in Sports and Exercise, 2013, 45, 1043-1050.	0.2	21
59	Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2012, 308, 2489.	3.8	571
60	Cholesterol Determines and Limits rHDL Formation from Human Plasma Apolipoprotein A-II and Phospholipid Membranes. Biochemistry, 2012, 51, 8627-8635.	1.2	8
61	Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nature Chemical Biology, 2012, 8, 342-349.	3.9	123
62	Abstract P220: The Effect of Diet-Induced Weight Loss on HDL Functionality in Individuals with Metabolic Syndrome: Investigating Alteration of the Initial Step in Reverse Cholesterol Transport as a Function of Plasma Lipoprotein Composition. Circulation, 2012, 125, .	1.6	0
63	Abstract 46: Cholesteryl Ester Transfer Protein Interactions with Lipoproteins: Insights into Mechanisms by Electron Microscopy and Molecular Dynamics Simulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, .	1.1	0
64	Abstract 105: Free Cholesterol Determines the Phospholipid Domain Size and Stability of rHDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, .	1.1	0
65	ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in Non-Hispanic White Americans from the Look AHEAD Clinical Trial. BMC Medical Genetics, 2011, 12, 89.	2.1	31
66	Apolipoprotein E Mediates Enhanced Plasma High-Density Lipoprotein Cholesterol Clearance by Low-Dose Streptococcal Serum Opacity Factor via Hepatic Low-Density Lipoprotein Receptors In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1834-1841.	1.1	25
67	Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of â€œHeart Positive,â€•a Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2236-2247.	1.8	53
68	Morphology and structure of lipoproteins revealed by an optimized negative-staining protocol of electron microscopy. Journal of Lipid Research, 2011, 52, 175-184.	2.0	101
69	Serum Opacity Factor Enhances HDLâ€Mediated Cholesterol Efflux, Esterification and Anti Inflammatory Effects. Lipids, 2010, 45, 1117-1126.	0.7	11
70	Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor. Journal of Lipid Research, 2010, 51, 297-308.	2.0	42
71	The Structure and Function of Serum Opacity Factor: A Unique Streptococcal Virulence Determinant That Targets High-Density Lipoproteins. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-16.	3.0	27
72	Speciated Human High-Density Lipoprotein Protein Proximity Profiles. Biochemistry, 2010, 49, 10656-10665.	1.2	25

#	Article	IF	Citations
73	Streptococcal Serum Opacity Factor Increases the Rate of Hepatocyte Uptake of Human Plasma High-Density Lipoprotein Cholesterol. Biochemistry, 2010, 49, 9866-9873.	1.2	18
74	HDL superphospholipidation enhances key steps in reverse cholesterol transport. Atherosclerosis, 2010, 209, 430-435.	0.4	33
75	Model of human low-density lipoprotein and bound receptor based on CryoEM. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1059-1064.	3.3	65
76	Mass spectrometric determination of apolipoprotein molecular stoichiometry in reconstituted high density lipoprotein particles. Journal of Lipid Research, 2009, 50, 1229-1236.	2.0	13
77	Apolipoprotein Modulation of Streptococcal Serum Opacity Factor Activity against Human Plasma High-Density Lipoproteins. Biochemistry, 2009, 48, 8070-8076.	1.2	18
78	Disruption of Human Plasma High-Density Lipoproteins by Streptococcal Serum Opacity Factor Requires Labile Apolipoprotein A-I. Biochemistry, 2009, 48, 1481-1487.	1.2	22
79	Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 1125-1132.	1.2	36
80	Human Plasma Lipoprotein Metabolism. , 2009, , 1-10.		2
81	Properties of the products formed by the activity of serum opacity factor against human plasma high-density lipoproteins. Chemistry and Physics of Lipids, 2008, 156, 45-51.	1.5	6
82	Cholesterol is a determinant of the structures of discoidal high density lipoproteins formed by the solubilization of phospholipid membranes by apolipoprotein A-I. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 245-253.	1.2	48
83	Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A2. Journal of Lipid Research, 2007, 48, 348-357.	2.0	54
84	Electronegative LDLs from familial hypercholesterolemic patients are physicochemically heterogeneous but uniformly proapoptotic. Journal of Lipid Research, 2007, 48, 177-184.	2.0	39
85	Sustained elevations in NEFA induce cyclooxygenase-2 activity and potentiate THP-1 macrophage foam cell formation. Atherosclerosis, 2007, 192, 49-55.	0.4	19
86	Serum Opacity Factor Unmasks Human Plasma High-Density Lipoprotein Instability via Selective Delipidation and Apolipoprotein A-I Desorption. Biochemistry, 2007, 46, 12968-12978.	1.2	41
87	Shear-induced Disulfide Bond Formation Regulates Adhesion Activity of von Willebrand Factor. Journal of Biological Chemistry, 2007, 282, 35604-35611.	1.6	97
88	Speciation of Human Plasma High-Density Lipoprotein (HDL):â€‰ HDL Stability and Apolipoprotein A-I Partitioning. Biochemistry, 2007, 46, 7449-7459.	1.2	45
89	Brain Uptake and Utilization of Fatty Acids, Lipids & Lipoproteins: Recommendations for Future Research. Journal of Molecular Neuroscience, 2007, 33, 146-150.	1.1	15
90	Modulation of angiogenic processes in cultured endothelial cells by low density lipoproteins subfractions from patients with familial hypercholesterolemia. Atherosclerosis, 2006, 186, 448-457.	0.4	34

#	Article	IF	Citations
91	Structures of Biologically Active Oxysterols Determine Their Differential Effects on Phospholipid Membranes. Biochemistry, 2006, 45, 10747-10758.	1.2	64
92	Heart positive: Design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials, 2006, 27, 518-530.	0.8	18
93	The unique role of apolipoprotein A-I in HDL remodeling and metabolism. Current Opinion in Lipidology, 2006, 17, 209-213.	1.2	38
94	Detergent-Mediated Phospholipidation of Plasma Lipoproteins Increases HDL Cholesterophilicity and Cholesterol Efflux via SR-Blâ€. Biochemistry, 2006, 45, 11514-11522.	1.2	24
95	N-Glycosylation is Required for Secretion-Competent Human Plasma Phospholipid Transfer Protein. Protein Journal, 2006, 25, 167-173.	0.7	5
96	Enhancing reverse cholesterol transport: the case for phosphatidylcholine therapy. Current Opinion in Lipidology, 2005, 16, 265-268.	1.2	17
97	Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. American Journal of Clinical Nutrition, 2005, 81, 1405-1410.	2.2	49
98	Plasma Factors Required for Human Apolipoprotein A-II Dimerization. Biochemistry, 2005, 44, 471-479.	1.2	12
99	Role of Oxysterol Structure on the Microdomain-Induced Microsolubilization of Phospholipid Membranes by Apolipoprotein A-Iâ€. Biochemistry, 2005, 44, 14376-14384.	1.2	25
100	The Polar Nature of 7-Ketocholesterol Determines Its Location within Membrane Domains and the Kinetics of Membrane Microsolubilization by Apolipoprotein A-I. Biochemistry, 2005, 44, 10423-10433.	1.2	64
101	Remodeling of Human Plasma Lipoproteins by Detergent Perturbation. Biochemistry, 2005, 44, 9714-9722.	1.2	26
102	Cardiovascular diseasesâ€"a major health risk in Asian Indians. Nutrition Research, 2005, 25, 515-533.	1.3	18
103	Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of â€˜systemic steatosisâ€™. Current Opinion in Lipidology, 2004, 15, 59-67.	1.2	64
104	Structure of Triglyceride-Rich Human Low-Density Lipoproteins According to Cryoelectron Microscopy. Biochemistry, 2003, 42, 14988-14993.	1.2	30
105	Structural and Functional Determinants of Human Plasma Phospholipid Transfer Protein Activity As Revealed by Site-Directed Mutagenesis of Charged Amino Acids. Biochemistry, 2003, 42, 4444-4451.	1.2	10
106	Low-Density Lipoprotein in Hypercholesterolemic Human Plasma Induces Vascular Endothelial Cell Apoptosis by Inhibiting Fibroblast Growth Factor 2 Transcription. Circulation, 2003, 107, 2102-2108.	1.6	147
107	Troglitazone Antagonizes Tumor Necrosis Factor-Î±-induced Reprogramming of Adipocyte Gene Expression by Inhibiting the Transcriptional Regulatory Functions of NF-ÎºB. Journal of Biological Chemistry, 2003, 278, 28181-28192.	1.6	168
108	Isolation, Characterization, and Functional Assessment of Oxidatively Modified Subfractions of Circulating Low-Density Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1083-1090.	1.1	98

#	Article	IF	Citations
109	Physical aspects of fatty acid transport between and through biological membranes. Advances in Molecular and Cell Biology, 2003, 33, 153-172.	0.1	2
110	Hyperhomocysteinemia accelerates atherosclerosis in cystathionine Î²-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood, 2003, 101, 3901-3907.	0.6	172
111	Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. Journal of Lipid Research, 2002, 43, 1170-1180.	2.0	253
112	Metabolic basis of HIV-lipodystrophy syndrome. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E332-E337.	1.8	119
113	Alcohol: Lipid metabolism and cardioprotection. Current Atherosclerosis Reports, 2002, 4, 107-112.	2.0	5
114	Cellular Transport of Nonesterified Fatty Acids. Journal of Molecular Neuroscience, 2001, 16, 109-116.	1.1	18
115	Choline Deficiency Causes Reversible Hepatic Abnormalities in Patients Receiving Parenteral Nutrition: Proof of a Human Choline Requirement: A Placeboâ€Controlled Trial. Journal of Parenteral and Enteral Nutrition, 2001, 25, 260-268.	1.3	203
116	EFFECT OF SIROLIMUS ON THE METABOLISM OF ApoB100- CONTAINING LIPOPROTEINS IN RENAL TRANSPLANT PATIENTS1. Transplantation, 2001, 72, 1244-1250.	0.5	114
117	Regulation of Acyl-Coenzyme A:Cholesterol Acyltransferase (ACAT) Synthesis, Degradation, and Translocation by High-Density Lipoprotein 2 at a Low Concentration. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2636-2642.	1.1	7
118	Hydrolysis of phospholipids by purified milk lipoprotein lipase. Clinica Chimica Acta, 2000, 291, 19-33.	0.5	21
119	Effect of Moderate Alcohol Consumption on Hypertriglyceridemia. Archives of Internal Medicine, 1999, 159, 981.	4.3	58
120	Efficient Nuclear Delivery of Antisense Oligodeoxynucleotides and Selective Inhibition of CETP Expression by Apo E Peptide in a Human CETPâ€“Stably Transfected CHO Cell Line. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2207-2213.	1.1	6
121	Role of cysteine residues in human plasma phospholipid transfer protein. The Protein Journal, 1999, 18, 193-198.	1.1	8
122	Short-term vitamin E supplementation before marathon running: a placebo-controlled trial. Nutrition, 1999, 15, 278-283.	1.1	33
123	Correlation of serum triglyceride and its reduction by Ï‰-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis, 1999, 143, 285-297.	0.4	161
124	Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Atherosclerosis, 1999, 144, 435-442.	0.4	35
125	Mechanism of action of probucol on cholesteryl ester transfer protein (CETP) mRNA in a Chinese hamster ovary cell line that had been stably transfected with a human CETP gene. Lipids and Lipid Metabolism, 1998, 1393, 153-160.	2.6	9
126	Surface Properties of Native Human Plasma Lipoproteins and Lipoprotein Models. Biophysical Journal, 1998, 74, 869-878.	0.2	32

#	Article	IF	Citations
127	Interaction of Î±-Tocopherol with Model Human High-Density Lipoproteins. Biophysical Journal, 1998, 75, 2923-2931.	0.2	13
128	Soluble Cell Adhesion Molecules in Hypertriglyceridemia and Potential Significance on Monocyte Adhesion. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 723-731.	1.1	196
129	Dyslipidemia, Diabetes, and Cell Adhesion Molecules. Medical Science Symposia Series, 1998, , 191-198.	0.0	0
130	Molecular and Macromolecular Specificity of Human Plasma Phospholipid Transfer Proteinâ€. Biochemistry, 1997, 36, 3645-3653.	1.2	109
131	Molecular Basis of Fish-Eye Disease in a Patient From Spain. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1382-1391.	1.1	18
132	The Lipoprotein and Coronary Atherosclerosis Study (LCAS): Design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Contemporary Clinical Trials, 1996, 17, 550-583.	2.0	31
133	A Metabolic Model for the Hypolipidemic and Antiatherogenic Effects of N-3 Fatty Acids: Effect of Omacor on Plasma Lipids. Medical Science Symposia Series, 1996, , 675-680.	0.0	1
134	Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia. Circulation, 1996, 93, 1334-1338.	1.6	256
135	Plasma factors affecting the in vitro conversion of high-density lipoproteins labeled with a non-transferable marker. Lipids and Lipid Metabolism, 1995, 1254, 13-21.	2.6	14
136	Effects of site-directed mutagenesis on the serine residues of human lecithin: Cholesterol acyltransferase. Lipids, 1994, 29, 803-809.	0.7	8
137	Free Radical-Induced Alterations in Endothelial Cell Function. Journal of Surgical Research, 1994, 56, 32-36.	0.8	18
138	Structure of Human Apolipoprotein D: Locations of the Intermolecular and Intramolecular Disulfide Links. Biochemistry, 1994, 33, 12451-12455.	1.2	43
139	Disulfide linked dimers of apolipoprotein D in urine. Electrophoresis, 1993, 14, 1086-1087.	1.3	9
140	The calcium uptake of the rat heart sarcoplasmic reticulum is altered by dietary lipid. Journal of Membrane Biology, 1993, 131, 35-42.	1.0	60
141	Mechanism of Cellular Phospholipid Efflux. Journal of Surgical Research, 1993, 55, 548-552.	0.8	3
142	Roles of cysteines in human lecithin:cholesterol acyltransferase. Biochemistry, 1993, 32, 3089-3094.	1.2	26
143	Effects of site-directed mutagenesis on the N-glycosylation sites of human lecithin:cholesterol acyltransferase. Biochemistry, 1993, 32, 8732-8736.	1.2	35
144	Spontaneous phospholipid transfer: development of a quantitative model. Biochemistry, 1991, 30, 5696-5700.	1.2	42

#	Article	IF	Citations
145	Unsaturated aminophospholipids are preferentially retained by the fast skeletal muscle CaATPase during detergent solubilization. Archives of Biochemistry and Biophysics, 1991, 286, 346-352.	1.4	31
146	Comparative specificity of plasma lecithin: Cholesterol acyltransferase from ten animal species. Lipids, 1991, 26, 416-420.	0.7	43
147	Effects of fluorophore structure and hydrophobicity on the uptake and metabolism of fluorescent lipid analogs. Chemistry and Physics of Lipids, 1991, 58, 111-119.	1.5	18
148	Analysis of the carbohydrate composition of glycoproteins by high-performance liquid chromatography. The Protein Journal, 1990, 9, 31-35.	1.1	14
149	Cyclopentanoid analogs of dipalmitoyl phosphatidic acid: effect of backbone geometry on thermotropic properties. Chemistry and Physics of Lipids, 1990, 55, 231-243.	1.5	6
150	Spectroscopic studies of the tyrosine residues of human plasma apolipoprotein A-II. BBA - Proteins and Proteomics, 1989, 999, 111-120.	2.1	8
151	Kinetics of tryptic hydrolysis as a probe of the structure of human plasma apolipoprotein A-II. BBA - Proteins and Proteomics, 1989, 999, 121-127.	2.1	6
152	Structure and conformational analysis of lipid-associating peptides of apolipoprotein B-100 produced by trypsinolysis. The Protein Journal, 1989, 8, 689-699.	1.1	25
153	High-performance liquid chromatographic analysis of acylated lipids containing pyrene fatty acids. Analytical Biochemistry, 1989, 178, 166-171.	1.1	13
154	Pyrene-labeled lipids: versatile probes of membrane dynamics in vitro and in living cells. Chemistry and Physics of Lipids, 1989, 50, 191-211.	1.5	62
155	Kinetics and mechanism of transfer of synthetic model apolipoproteins. Biochemistry, 1988, 27, 7881-7886.	1.2	7
156	Apolipoproteins C-I, C-II, and C-III: kinetics of association with model membranes and intermembrane transfer. Biochemistry, 1988, 27, 4500-4505.	1.2	28
157	Transbilayer diffusion of phospholipids: dependence on headgroup structure and acyl chain length. Biochimica Et Biophysica Acta - Biomembranes, 1988, 938, 155-166.	1.4	215
158	Control of Spontaneous Lipid and Protein Transport. Advances in Experimental Medicine and Biology, 1988, 243, 173-177.	0.8	3
159	Phospholipids Chiral at Phosphorus. 13. Stereochemical Comparison of Phospholipase A₂, Lecithin-Cholesterol Acyl Transferase, and Platelet-Activating Factor. Phosphorous and Sulfur and the Related Elements, 1987, 30, 601-604.	0.2	6
160	Chapter 3 Lipid-protein interactions and lipoprotein reassembly. New Comprehensive Biochemistry, 1987, , 95-127.	0.1	14
161	Effect of pressure on phospholipid translocation in lipid bilayers. Journal of the American Chemical Society, 1987, 109, 4759-4760.	6.6	23
162	The helical hydrophobic moment avoids prolines in phospholipid-binding proteins. Biochemical and Biophysical Research Communications, 1986, 139, 202-208.	1.0	9

#	Article	IF	Citations
163	[1] Introduction to the plasma lipoproteins. Methods in Enzymology, 1986, 128, 3-41.	0.4	313
164	[23] Thermodynamics of apolipoprotein-phospholipid association. Methods in Enzymology, 1986, 128, 403-413.	0.4	9
165	The primary structure of apolipoprotein A-I from rabbit high-density lipoprotein. FEBS Journal, 1986, 160, 427-431.	0.2	22
166	Equilibrium of apoproteins between high density lipoprotein and the aqueous phase: Modelling of in vivo metabolism. Journal of Theoretical Biology, 1985, 112, 183-192.	0.8	9
167	Identification of peptides containing tryptophan, tyrosine, and phenylalanine using photodiode-array spectrophotometry. Analytical Biochemistry, 1985, 145, 67-72.	1.1	23
168	Lateral distribution of phospholipid and cholesterol in apolipoprotein A-I recombinants. Biochemistry, 1985, 24, 7110-7116.	1.2	38
169	Interfacial properties of model membranes and plasma lipoproteins containing ether lipids. Biochemistry, 1985, 24, 6973-6978.	1.2	65
170	Abnormal interaction of the human apolipoprotein A-I variant [Lys107âţ'0] with high density lipoproteins. Biochemical and Biophysical Research Communications, 1985, 133, 856-862.	1.0	12
171	Fluorescence assay of the specificity of human plasma and bovine liver phospholipid transfer proteins. Lipids and Lipid Metabolism, 1985, 835, 124-131.	2.6	38
172	Reversible folding reactions of human apolipoprotein A-I: pressure and guanidinium chloride effects. Lipids and Lipid Metabolism, 1985, 836, 215-221.	2.6	8
173	Spontaneous and plasma factor-mediated transfer of pyrenyl cerebrosides between model and native lipoproteins. Lipids and Lipid Metabolism, 1985, 837, 27-34.	2.6	19
174	Isolation and specificity of rat lecithin : Cholesterol acyltransferase: Comparison with the human enzyme using reassembled high-density lipoproteins containing ether analogs of phosphatidylcholine. Lipids and Lipid Metabolism, 1985, 833, 456-462.	2.6	40
175	The Role of Hydrophobicity in the Structure of the Human Plasma Lipoproteins. , 1985, 183, 85-97.		0
176	In vitro transfer of phosphatidylcholines and their ether analogs by a human and rat plasma exchange factor. Biochemical and Biophysical Research Communications, 1984, 119, 452-457.	1.0	6
177	In vitro binding of synthetic acylated lipid-associating peptides to high-density lipoproteins: effect of hydrophobicity. Biochemistry, 1984, 23, 5337-5342.	1.2	28
178	Pyrenedodecanoylcarnitine and pyrenedodecanoyl coenzyme A: kinetics and thermodynamics of their intermembrane transfer. Biochemistry, 1984, 23, 6426-6432.	1.2	15
179	Effect of hydrostatic pressure on the transfer of a fluorescent phosphatidylcholine between apolipoprotein-phospholipid recombinants. Journal of the American Chemical Society, 1984, 106, 3317-3319.	6.6	9
180	Measurement and prediction of the rates of spontaneous transfer of phospholipids between plasma lipoproteins. Lipids and Lipid Metabolism, 1984, 794, 274-280.	2.6	92

#	Article	IF	Citations
181	Thermodynamics of lipid-protein association and the activation of lecithin:Cholesterol acyltransferase by synthetic model apolipopeptides. Lipids and Lipid Metabolism, 1984, 793, 149-156.	2.6	18
182	Transfer of polycyclic aromatic hydrocarbons between model membranes: Relation to carcinogenicity. Chemico-Biological Interactions, 1983, 44, 237-246.	1.7	17
183	A simplified approach to resonance energy transfer in membranes, lipoproteins and spatially restricted systems. Biophysical Chemistry, 1983, 17, 139-152.	1.5	26
184	Transport of biological lipophiles: effect of lipophile structure. Journal of the American Chemical Society, 1983, 105, 2440-2445.	6.6	96
185	The properties of membranes formed from cyclopentanoid analogues of phosphatidylcholine. Biochimica Et Biophysica Acta - Biomembranes, 1983, 731, 373-377.	1.4	18
186	Helical amphipathic moment: application to plasma lipoproteins. FEBS Letters, 1983, 159, 17-23.	1.3	28
187	Structure and Dynamics of Human Plasma Lipoproteins. , 1983, , 205-244.		10
188	Plasma Lipoproteins: Fluorescence as a Probe of Structure and Dynamics. , 1983, , 163-202.		1
189	(1-Pyrenebutyryl)carnitine and 1-pyrenebutyryl coenzyme A: fluorescent probes for lipid metabolite studies in artificial and natural membranes. Biochemistry, 1982, 21, 2990-2996.	1.2	21
190	Kinetics and mechanism of the spontaneous transfer of fluorescent phosphatidylcholines between apolipoprotein-phospholipid recombinants. Biochemistry, 1982, 21, 3630-3636.	1.2	116
191	Fluorescent cholesteryl esters in the core of low density lipoprotein. Biochemical and Biophysical Research Communications, 1982, 105, 674-680.	1.0	9
192	Interaction of vitamin E with saturated phospholipid bilayers. Biochemical and Biophysical Research Communications, 1982, 106, 842-847.	1.0	104
193	Kinetics of spontaneous and plasma-stimulated sphingomyelin transfer. Lipids and Lipid Metabolism, 1982, 712, 169-176.	2.6	41
194	Action of lecithin:Cholesterol acyltransferase on model lipoproteins. Lipids and Lipid Metabolism, 1982, 713, 494-503.	2.6	44
195	Thermodynamics of Lipid-Protein Association in Human Plasma Lipoproteins. Biophysical Journal, 1982, 37, 175-177.	0.2	10
196	Mechanism of Association of Human Plasma Apolipoproteins with Dimyristoylphosphatidylcholine. Biophysical Journal, 1982, 37, 177-179.	0.2	27
197	Thermodynamics of lipid-protein interactions: interaction of apolipoprotein A-II from human plasma high-density lipoproteins with dimyristoylphosphatidylcholine. Biochemistry, 1981, 20, 1575-1584.	1.2	72
198	Physical properties of lipid-protein complexes formed by the interaction of dimyristoylphosphatidylcholine and human high-density apolipoprotein A-II. Biochemistry, 1981, 20, 1569-1574.	1.2	39

#	Article	IF	Citations
199	Kinetics and mechanism of association of human plasma apolipoproteins with dimyristoylphosphatidylcholine: effect of protein structure and lipid clusters in reaction rates. Biochemistry, 1981, 20, 6630-6635.	1.2	66
200	Raman spectroscopy of the thermal properties of reassembled high-density lipoprotein: apolipoprotein A-I complexes of dimyristoylphosphatidylcholine. Biochemistry, 1981, 20, 656-661.	1.2	23
201	Thermodynamics of lipidâ€"proiein associations: the enthalpy of binding of Apo C-III to synthetic phosphatidylcholines. Canadian Journal of Biochemistry, 1981, 59, 700-708.	1.4	11
202	Human plasma high density apolipoprotein A-I: Effect of protein-protein interactions on the spontaneous formation of a lipid-protein recombinant. Biochemical and Biophysical Research Communications, 1981, 99, 466-474.	1.0	26
203	Effect of saturated and polyunsaturated fat diets on the composition and structure of human low density lipoproteins. Atherosclerosis, 1980, 36, 299-314.	0.4	63
204	Mechanism and kinetics of transfer of a fluorescent fatty acid between single-walled phosphatidylcholine vesicles. Biochemistry, 1980, 19, 108-116.	1.2	198
205	Serum lipoprotein structure: resonance energy transfer localization of fluorescent lipid probes. Biochemistry, 1980, 19, 1294-1301.	1.2	59
206	Reconstituted low density lipoprotein: A vehicle for the delivery of hydrophobic fluorescent probes to cells. Journal of Supramolecular Structure, 1979, 10, 467-478.	2.3	104
207	A review of the unique features of HDL apoproteins. Lipids, 1979, 14, 428-434.	0.7	25
208	Kinetics of lipid-protein interactions: effect of cholesterol on the association of human plasma high-density apolipoprotein A-I with L-.alpha.-dimyristoylphosphatidylcholine. Biochemistry, 1979, 18, 574-579.	1.2	112
209	THE ELECTRONIC SPECTROSCOPY OF PYRIMIDINES: THE EFFECT OF COVALENTLY BONDED SULFUR ON THE PHOSPHORESCENCE AND ABSORPTION SPECTRA. Photochemistry and Photobiology, 1978, 27, 625-628.	1.3	18
210	Lipoprotein-apoprotein exchange in aqueous systems: Relevance to the occurrence of APOA-I and APOC proteins in a common particle. Biochemical and Biophysical Research Communications, 1978, 85, 408-414.	1.0	42
211	N-(2-Naphthyl)-23,24-dinor-5-cholen-22-amin-3Î²-ol, a fluorescent cholesterol analog. Biochemistry, 1978, 17, 2689-2696.	1.2	31
212	Kinetics of lipid-protein interactions: interaction of apolipoprotein A-I from human plasma high density lipoproteins with phosphatidylcholines. Biochemistry, 1978, 17, 1183-1188.	1.2	226
213	Lipid binding by fragments of apolipoprotein C-III-1 obtained by thrombin cleavage. Biochemistry, 1977, 16, 5427-5431.	1.2	54
214	Internal heavy atom studies on the triplet state of dimethyl- and dihaloxanthones. The Journal of Physical Chemistry, 1976, 80, 508-511.	2.9	9
215	Solvent and substituent effects in aromatic carbonyl compounds: the lowest triplet states of xanthone and xanthone-18O1. Molecular Physics, 1976, 31, 1393-1406.	0.8	25
216	THE SPECTROSCOPY AND PHOTOCHEMISTRY OF ENAMINONITRILES INCLUDING THE SYNTHESIS AND IDENTIFICATION OF CIS-Î²-AMINOACRYLONITRILE. Photochemistry and Photobiology, 1976, 24, 217-222.	1.3	3

#	Article	IF	Citations
217	Synthesis and substituent effects in the nuclear magnetic resonance and mass spectra of dimethyl- and dihaloxanthones. Journal of Organic Chemistry, 1975, 40, 2088-2091.	1.7	18
218	Photo-oxidation in the synthesis of17O and18O labelled compounds: Synthesis of xanthone-18O1. Journal of Labelled Compounds, 1974, 10, 413-417.	0.3	2
219	Solvent and substituent effects in aromatic carbonyl compounds: The triplet state of flavone. Spectrochimica Acta Part A: Molecular Spectroscopy, 1974, 30, 953-959.	0.1	10
220	Phase transitions in bilamellar vesicles. Measurements by pyrene excimer fluorescence and effect on transacylation by lecithin-cholesterol acyltransferase. Biochemistry, 1974, 13, 2828-2836.	1.2	127
221	Origin of the anomalous phosphorescence of aromatic ketones. Xanthone in 3-methylpentane. Chemical Physics Letters, 1973, 22, 403-405.	1.2	21
222	Viscosity of the hydrocarbon region of micelles. Measurement by excimer fluorescence. Journal of the American Chemical Society, 1973, 95, 3136-3140.	6.6	144
223	Impurity phosphorescence in methylene anthrone. Journal of Chemical Physics, 1973, 58, 3116.	1.2	1
224	Absorption and emission spectra of aromatic ketones and their medium dependence. Excited states of xanthone. Journal of the American Chemical Society, 1971, 93, 6429-6436.	6.6	91